{"version":"1.0","provider_name":"MedCity News","provider_url":"https:\/\/medcitynews.com","author_name":"Frank Vinluan","author_url":"https:\/\/medcitynews.com\/author\/fvinluan\/","title":"KalVista Drug Gets FDA Approval for Treating Acute Swelling Attacks From Rare Disease - MedCity News","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"qNJjFiwFeC\"><a href=\"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/\">KalVista Drug Gets FDA Approval for Treating Acute Swelling Attacks From Rare Disease<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/embed\/#?secret=qNJjFiwFeC\" width=\"600\" height=\"338\" title=\"&#8220;KalVista Drug Gets FDA Approval for Treating Acute Swelling Attacks From Rare Disease&#8221; &#8212; MedCity News\" data-secret=\"qNJjFiwFeC\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/07\/KalVista_PillPack_resized_cropped.jpg","thumbnail_width":843,"thumbnail_height":562,"description":"KalVista Pharmaceuticals\u2019 Ekterly is now FDA approved for treating acute swelling attacks from hereditary angioedema. The KalVista tablet provides an alternative to injectable or infused HAE medications from companies such as Takeda Pharmaceutical and CSL Behring."}